Neutralisation of IL12 p40 or IL23 p40 does not block inflammation in multiple sclerosis.
Martin
Roland
R
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D018664:Interleukin-12 / Q000037:antagonists & inhibitors* / Q000276:immunology; D053759:Interleukin-23 / Q000037:antagonists & inhibitors* / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D017211:Treatment Failure; D014409:Tumor Necrosis Factor-alpha / Q000187:drug effects / Q000276:immunology
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D053759:Interleukin-23; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12